Clinical Use of Amrinone (a Selective Phosphodiesterase III Inhibitor) in Reconstructive Surgery
- 1 December 2001
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Plastic and Reconstructive Surgery
- Vol. 108 (7), 1931-1937
- https://doi.org/10.1097/00006534-200112000-00013
Abstract
Amrinone is a selective phosphodiesterase III inhibitor that increases cyclic adenosine monophosphate by preventing its breakdown. It is effective in the treatment of congestive heart failure because of its ability to increase myocardial contractility and vascular smooth muscle relaxation. This study was designed to clarify the potential efficacy of amrinone in plastic surgery by clinically assessing its ability to enhance flap blood flow after reconstructive surgery and relieve intraoperative vasospasm. Its effects were compared with those of prostaglandin E1 and lidocaine, which are widely approved agents for improving the hemodynamics of flaps. In the first clinical study, the effects on flap blood flow after flap transfers were investigated. Twenty-six patients underwent reconstructive surgery with vascularized free or pedicled flaps. Blood flow was measured before and 60 minutes after intravenous infusion of lactated Ringer solution (control), amrinone (10 μg/kg/min), or prostaglandin E1 (10 ng/kg/min) using a laser Doppler flowmeter. In the second study, the effects on relief of vasospasm during operation were evaluated. The blood flow of 28 island flaps was measured by laser Doppler flowmetry immediately after flap elevation and 10 minutes after topical application of saline (control), amrinone (5 mg/ml), or lidocaine (10%) to the pedicle in an attempt to resolve the vasospasm. In both clinical studies, the effects of amrinone were statistically no less than those of prostaglandin E1 and lidocaine. The results show that amrinone positively influences the microcirculatory blood flow of transferred flaps and relieves intraoperative vasospasm in clinical cases. The present study suggests that amrinone could be useful for postoperative and intraoperative care in reconstructive surgery. (Plast. Reconstr. Surg. 108: 1931, 2001.)Keywords
This publication has 10 references indexed in Scilit:
- Topical Application of Amrinone (a Selective Phosphodiesterase III Inhibitor) for Relief of VasospasmJournal of Surgical Research, 2000
- Amrinone, a Selective Phosphodiesterase III Inhibitor, Improves Microcirculation and Flap Survival: A Comparative Study with Prostaglandin E1Journal of Surgical Research, 1998
- Phosphodiesterase III inhibitors: Long-term risks and short-term benefitsCardiovascular Drugs and Therapy, 1993
- Augmentation of Skin Flap Survival by Selective Intraarterial Infusion of Prostaglandin E1: Experimental and Clinical StudiesAnnals of Plastic Surgery, 1993
- Prostacyclin and prostanoid modifiers aid ischemic skin flap survivalJournal of Surgical Research, 1991
- Effect of Intravenous Prostaglandin E1 on Experimental FlapsAnnals of Plastic Surgery, 1987
- Effect of Intraarterial Prostacyclin on Survival of Skin Flaps in the Pig: Biphasic ResponseAnnals of Plastic Surgery, 1984
- Augmentation of Surviving Flap Area by Intraarterial Vasodilators Administered Through Implantable PumpsAnnals of Plastic Surgery, 1983
- The peripheral hemodynamics of exogenously administered prostaglandin E1 during major venous occlusion in the dogJournal of Surgical Research, 1981
- The effect of 16, 16-dimethyl prostaglandin E2 on autogenous flap survival in the ratJournal of Surgical Research, 1981